Estimating Public Economic Gains from Early Breast Cancer and Curative Treatment: A Case Study in Human Epidermal Growth Factor Receptor (HER-2) Positive Targeted Therapies.
Svenn Alexander KommandantvoldNikos KotsopoulosIsabel MonteiroAna LadeirasAndrew HoganFelipe Barboza Magalhães de AraujoMark P ConnollyPublished in: Oncology and therapy (2024)
Women diagnosed with HER2-positive eBC were estimated to pay less lifetime gross taxes and receive more in sickness benefits compared with healthy women. Treatments that improve outcomes are likely to offer fiscal gains for government from improved work force participation.
Keyphrases
- epidermal growth factor receptor
- early breast cancer
- polycystic ovary syndrome
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- pregnancy outcomes
- healthcare
- cervical cancer screening
- physical activity
- breast cancer risk
- single molecule
- rectal cancer
- induced pluripotent stem cells
- type diabetes
- pregnant women
- health insurance
- metabolic syndrome
- prognostic factors
- children with cerebral palsy
- emergency department
- combination therapy